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Pharmaceutical R&D productivity has declined over the last decade despite increasing investments. Recent trends,
however, indicate a potential reversal of this trend fueled by a wave of new biologics, vaccines and highly selective
NCEs directed against targets validated by human genetics, focus on new disease areas including orphan and
genetic diseases and more precise tailoring of medicines to their target populations.Precision medicine
Precision Medicine [1,2] is an approach to discovering
and developing medicines and vaccines that deliver su-
perior outcomes for patients, by integrating clinical and
molecular information to understand the biological basis
of disease. This approach leads to better selection of dis-
ease targets and identification of patient populations that
experience better clinical outcomes. Ultimately, the po-
tential of Precision Medicine is that it will yield treat-
ments that deliver clinically significant treatment effects,
with favorable safety profiles. When appropriate, these
new treatments are focused on a particular sub- group
of patients with certain genotypic and/or phenotypic
characteristics that make them more likely to benefit or
less likely to experience side effects. A related concept,
“Personalized Medicine”, has been defined by President’s
Council of Advisors on Science and Technology
(PCAST) as “the tailoring of medical treatment to the
individual characteristics of each patient to classify indi-
viduals into subpopulations that differ in their suscepti-
bility to a particular disease or their response to a
specific treatment [3]”. Thus, products and diagnostics
developed through Precision Medicine facilitate the prac-
tice of Personalized Medicine.Precision medicine case examples
Developing a therapeutic for a targeted population:
Crizotinib
Oncology is the frontier of Precision Medicine and typ-
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reproduction in any medium, provided the origcrizotinib, an ALK inhibitor for ALK fusion proteins in
lung cancer), mutations (as in the case of vemurafinib, a
BRAF inhibitor for melanoma patients with the BRAF
V600E mutation) and protein over- expression (e.g. Tras-
tuzumab a HER2-targeted antibody for breast cancer).
Crizotinib was identified in 2005 as a cMET (and ALK/
ROS1) kinase inhibitor. In 2007, contemporaneously
with dose escalation in Phase I studies, academic
researchers in Japan found that about 5% of patients
with non-small cell lung cancer (NSCLC), typically
younger non-smokers, carry an EML4-ALK fusion gene
leading to constitutive activation of ALK kinase. The
Phase I protocol was amended to include patients with
ALK-positive tumors, and within a few months of enrol-
ling the first patients with the ALK mutation, objective
tumor responses were seen in ALK-positive NSCLC
patients. An impressive objective response rate (ORR) of
over 60% and a disease control rate of over 80% which
was significantly better than the expected ORR of less
than 20% in matched, historical control patients were
observed. Based on these data, a rolling submission in
the first half of 2011 to the US FDA led to accelerated
approval in less than 6 months following submission.
The ability to respond quickly to the ALK rearrange-
ment discovery in 2007, along with the successful devel-
opment of a FDA-approved ALK companion diagnostic
assay was instrumental in enabling FDA approval only
five years after the start of the first clinical studies. Had
the clinical trials been conducted in a non-selected
NSCLC patient population, the strong clinical efficacy
would likely not have been evident in Phase I/II studies,
the therapeutic benefit likewise may not have been seen
in a randomized Phase III study, and this compound. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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demonstrates the potential and value of Precision
Medicine.
Leveraging insight from human genetics to create novel
therapeutics: PCSK9
The breakthrough in high throughput human genetics
has enabled easy identification of the genetic cause for
many “extreme diseases phenotypes”. This insight may
lead to treatment of affected individuals as well as
broader patient populations. One example of such an ex-
treme phenotype relates to individuals with a rare loss-
of-function mutation in the PCSK9 gene – but who are
otherwise normal. These individuals have very low LDL-
cholesterol as well as a markedly reduced incidence of
cardiovascular disease. Based on these genetic findings
and the biological knowledge that normal PCSK9 pro-
tein in the blood inhibits cellular uptake of LDL choles-
terol several companies have developed antibodies that
binds to and reduces the function of PCSK9 protein.
Early clinical data suggest that treatment with one such
antibody RN316 results in very significant and long last-
ing declines in LDL- cholesterol in the majority of
patients with elevated LDL cholesterol. If these prelimin-
ary data are confirmed in broader testing, RN316 ther-
apy may be particularly useful for treating high risk
patients who do not respond adequately to intensive sta-
tin therapy.
Leveraging information about cytokine signaling
pathways to create novel anti-inflammatory drugs:
Lebrikizumab and tofacitinib
Direct targeting of pro-inflammatory cytokines has deliv-
ered several therapeutics notably TNFα and IL-6
neutralizing antibodies. In the case of lebrikizumab, an
anti- IL-13 antibody, the underlying biology (e.g., IL-13
stimulated bronchial proteins) was used to identify a
biomarker (periostin) for identification of Phase II trial
subjects who benefited the most from the agent. This
may allow smaller phase III trials with better statistical
outcome in the targeted population of patients with
moderate to severe asthma. The oral JAK inhibitor
Tofacitinib takes a novel approach, targeting the intra-
cellular signaling pathways that operate as hubs in the
inflammatory cytokine network. More specifically JAK3
mediates signaling through the common gamma chain
of IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 cytokine
receptor complexes, explaining the broad action of
tofacitinib. Tofacitinib is being investigated as a targeted
immune-modulator and disease-modifying therapy for
Rheumatoid Arthritis (RA) and has the potential to be-
come an important new treatment for RA patients.
Phase 3 data showed that patients who received 5 mg or
10 mg tofacitinib have a statistically significant andclinically meaningful improvement in disease scores
(ACR20, ACR50 and ACR70) vs. placebo. Tofacitinib is
also being explored as a potential treatment for psoriasis,
and inflammatory bowel disease. Precision Medicine
may further help define the positioning of tofacitinib in
these diseases as it was in RA trials where patients were
selected who had moderate to severe disease as mea-
sured by disease activity score to identify a population
with significant disease burden and risk of progressive
joint injury.
Understanding the molecular basis of adverse drug
events to create safer therapeutics
Another aspect of Precision Medicine is the role safety
plays in selecting patients for treatment to avoid drug-
related adverse events. Analysis of the FDA Table of
Pharmacogenomic Biomarkers in Drug Labels (96 drugs
in total) demonstrated that 62% of the biomarkers are
used to exclude patients or adjust dose based on safety-
related concerns, and 31% are used for efficacy [4,5].
The majority of safety biomarkers measure polymorph-
isms in genes encoding metabolizing enzymes and drug
transporters with the objective of achieving adequate
drug exposure. Other safety biomarkers focusing on
idiosyncratic safety issues most often measure enzyme
deficiencies and immune response (e.g. HLA genes). For
Pharmacodynamic adverse drug events, cetuximab and
panitumumab are monoclonal antibodies for colorectal
cancer that target EGFR. Patients with activating muta-
tions in the KRAS gene downstream of EGFR receive no
therapeutic benefit from treatment. Therefore, in these
patients, treatment skews the risk-benefit profile toward
toxicity without benefit.
Strategic application of precision medicine
Precision Medicine success is predicated on the appro-
priate selection of projects that benefit from its applica-
tion, ideally fulfilling the following criteria:
 Strong human biology data package with evidence
that the drug target is a critical driver of disease and
its modulation is likely to produce a meaningful
clinical benefit.
 Evidence of downstream pharmacodynamic effects
as a consequence of target engagement.
 Biomarkers predictive of clinical benefit (both for
efficacy and safety/toxicity) to allow population
stratification and associated diagnostic markers if
appropriate.
Biomarker and diagnostic marker discovery and
development
The development of biomarkers - some of which may
ultimately translate into companion diagnostics - is a
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Broadly speaking, biomarkers can be categorized in
terms of disease, mechanism or outcome. Those that are
prognostic of disease progression or predictive of out-
come will form the basis of companion diagnostics. It is
critical to develop biomarkers at the earliest stages of
drug discovery and, where based on preclinical models,
translate them effectively into the clinic. The develop-
ment of biomarkers to segment diseases into better
understood molecularly-characterized subtypes depends
on access to well-defined patient populations and patient
biologic samples along with longitudinal clinical data
and medical and treatment histories. Clinical trials or
methodology studies will be required not only to dem-
onstrate fit-for-purpose validation or qualification of
specific biomarker candidates, but also to identify new
biomarker candidates related to treatment outcomes,
which in turn can be used for early research purposes.
The development of a comprehensive biomarker plan at
the very early stages (e.g. lead development) of drug de-
velopment enables the generation of appropriate pre-
clinical and translational markers and delivery of a quali-
fied, fit-for-purpose biomarker to be incorporated into
clinical trials.
Like therapies, biomarkers are validated in clinical trials.
A typical biomarker is first evaluated in Phase I/II clinical
trials. If the preliminary data indicates a clinically signifi-
cant difference in outcome for patients based on a given
biomarker, its predictive utility needs to be confirmed
(replicated) in a prospectively designed study. A clinically
significant improvement in outcome (therapeutic index)
would be required for the biomarker to be validated for
use in patient selection. Some of these biomarkers may be
translated into a companion diagnostic that can be used
to identify an appropriate subpopulation that should (or
should not) receive treatment. Ideally, a drug and its com-
panion diagnostic would be developed contemporaneously
with the clinical relevance and technical performance cri-
teria established using data from the clinical development
program before NDA filing.
Enabling technologies - creation of a strong data
package
The ultimate end product of any R&D program is data
that can support regulatory and intellectual property fil-
ings, inform a product label and support the manufac-
ture and sale of the drug. Generation and advanced
analysis of molecular and clinical data from studies are
primary enablers for Precision Medicine decision mak-
ing. Internal and external information can support and
define decisions regarding target selection, pre-clinical
and clinical experiment design, biomarker identification,
disease modeling, and patient stratification. A wealth of
human biology insight may be found in clinical, medicaland basic biology data sets in academia and in pharma-
ceutical companies. These data are obtained from a
range of resources including clinical trials, electronic
medical records, personal health records, ‘omics’, sequen-
cing and genotyping experiments. Opportunities exist to
develop shared industry solutions relating to validation
of markers, and to collaborate with commercial and not-
for-profit entities on bio-specimens, clinical data, regis-
tries and other data relating to human biology.
Advances in lab technology over the last 10 years have
increased the scale of internal and external data gener-
ation and increased the relevance to pharmaceutical
companies. This trend will continue providing increas-
ingly granular insight into the molecular drivers and cor-
relates of clinical outcomes. Biomarker technologies that
generate quantitative data, can be performed on small
amounts of tissue (e.g. tumor biopsies), are multiplex-
able and/or allow for in vivo or minimally invasive as-
sessment are particularly attractive.
Regulatory considerations
Precision Medicine will hopefully lead to scientifically
selected, well-defined populations enriched for respon-
ders, enabling smaller databases to support efficacy. The
appropriate selection of patient populations for clinical
trials has the potential to lead to earlier regulatory submis-
sions, shorter and more predictable timing to approvals,
and faster and more focused product launches. A higher
rate of new drug approvals may also be expected due to
stratification of populations when efficacy or risk consid-
erations differ in various subpopulations, resulting in more
compelling overall product risk/benefit (therapeutic index)
versus current therapies, and better odds of approval.
These benefits, however, come with some challenges. First,
labels will be more narrowly crafted to focus the approved
indication on the appropriate population . In addition, the
regulatory pathway of novel therapies developed through
Precision Medicine may be complicated by the accom-
panying selection method by which the population is
defined. If a novel biomarker is to be used, and the pro-
duct’s labeling defines the approved population by this
measure, regulations require that the means of measuring
the biomarker be commercially available. Increasingly, this
is driving simultaneous drug and companion diagnostics
development programs.
Commercial and market access considerations
Precision Medicine requires careful evaluation of the com-
mercial and market access landscape to accurately identify
the commercial opportunity. Therapies developed through
Precision Medicine may command a higher price and
greater reimbursement, driven by enhanced value of ther-
apy to patient and payer, improved patient compliance
and increased level of trust and confidence among all
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there may be fewer adverse events and therefore less po-
tential for market withdrawal and fewer label restrictions.
However, these advantages are balanced by a more fo-
cused and fragmented market that might limit sales
potential.
For these reasons, it is important to build a strong
case for the medicine’s clinical benefit and therapeutic
index in the defined patient population. Such a case
could be supported through health economic considera-
tions and/or health technology assessments which are
increasingly being used by public health bodies to make
recommendations on reimbursement of medicines and
devices. From a payer perspective, there are many bene-
fits of Precision Medicine that enhance the value prop-
osition. These include better risk estimation and
treatment optimization, diagnostics that can screen high
risk patients to identify a specific disease early, and tests
that provide healthcare providers and payers with a
broad risk profile for a specific disease to identify appro-
priate patients for a given targeted therapy. Importantly,
the ability to identify those patients who will have higher
treatment response rates and will experience fewer ad-
verse events and/or side effects will serve as a powerful
driver of value as payers balance increasing healthcare
costs against healthcare funding constraints and shrink-
ing budgets. Payers are wary of covering diagnostics
when there is a not a clear link to a health economics or
treatment benefit, so the scientific and commercial ra-
tionale for its use must be sound.
Legal and ethical considerations
Appropriate handling of the ethical and legal challenges
for clinical trial investigators, regulatory authorities,
patients, payers and other stakeholders that arise out of
Precision Medicine is imperative to increase public con-
fidence, the viability of data collection efforts and suc-
cessful commercialization of personalized medicine
products. A key area relates to privacy, confidentiality
and patients’ rights issues, and the evolving ethical issues
around collection of samples and data for future, “sec-
ondary” research that could involve new subpopulations,
biomarkers, and other indications relevant to Precision
Medicine. An additional consideration is the legal uncer-
tainty regarding patentability and enforceability of perso-
nalized medicine method claims, which seek to cover
the two-step process of determining the level of a bio-
marker (e.g., metabolite) in a diagnostic test and then
administering the appropriate medication).
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